Brainstorm Cell Therapeutics (NASDAQ:BCLI) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.11, Morningstar.com reports.
Shares of Brainstorm Cell Therapeutics (BCLI) opened at $3.41 on Friday. Brainstorm Cell Therapeutics has a 12 month low of $2.88 and a 12 month high of $5.18. The stock has a market capitalization of $66.75, a P/E ratio of -12.63 and a beta of 1.95.
BCLI has been the topic of a number of analyst reports. Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, December 27th. ValuEngine cut Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 21st.
WARNING: This piece was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3252857/brainstorm-cell-therapeutics-bcli-posts-earnings-results-beats-expectations-by-0-11-eps.html.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.